Department of Health and Human Services, through National Institutes of Health, awarded Stress Therapeutics, Inc. of San Diego, CA $1,994,840 under the SBIR program (Phase I), with work starting 2025-05-15 and running to 2027-04-30. It is one of 2 SBIR and STTR awards Stress Therapeutics, Inc. received in the last two years, $2,344,445 in all. Each figure links to the federal record.
The award
| Recipient | Stress Therapeutics, Inc. (San Diego, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $1,994,840 |
| Period of performance starts | 2025-05-15 |
| Period of performance ends | 2027-04-30 |
| Award number | U43AA032129 (grant, CFDA 93.273) |
| Assistance listing | 93.273, Alcohol Research Programs |
| Place of performance | San Diego, San Diego County, CA |
| Recipient registry id (UEI) | VLU8DHDM9JZ3 |
Want the whole picture on Stress Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Stress Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Stress Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Investigational new drug (ind)-enabling study for a new therapeutic for alcohol use disorder (aud) - summary. While the stress response is essential for survival, IT can become dysregulated. Overactivation of the hypotha
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-05-18 | Continuation | 000 | $995,447 |
| 2025-05-15 | New | 000 | $999,393 |
Investigational new drug (ind)-enabling study for a new therapeutic for alcohol use disorder (aud) - summary. While the stress response is essential for survival, IT can become dysregulated. Overactivation of the hypothalamic-pituitary-adrenal (hpa) axis plays a mechanistic role in the pathophysiology of alcohol use disorder (aud). This SBIR Phase I proposal in response to PAR-22-102 is aimed at initiating investigational new drug (ind)-enabling studies for an innovative first-in-class therapeutic aimed at the chronic management of pathologic hpa axis hyperactivity for the treatment of aud. Evidence indicates that preventing excessive hpa activation in the setting of aud will restore hpa negative feedback and reset the system at more physiological levels, reducing motivation for drinking and relapse. Therapeutics to modulate the hpa axis have been under research for decades. Several medications for hpa axis hyperactivity have been studied extensively but have generally been unsatisfactory due to limited efficacy on the hpa and side effects. Thus, there is a considerable unmet medical need for identification of novel therapeutics to normalize hpa hyperactivity that are effective and tolerable for long-term use. This Phase I SBIR will manufacture and validate the test article for investigational new drug (ind)-enabling studies and initiate ind-enabling studies including the devel ...
From the federal award record.
Other SBIR and STTR awards to Stress Therapeutics, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-06-01 | Department of Health and Human Services | SBIR Phase I | $349,605 | Lead optimization of a therapeutic candidate for alzheimer’s disease - summary. Overactiva (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Stress Therapeutics, Inc.Look up Stress Therapeutics, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.